Alpha 1 Antitrypsin Deficiency Associated Liver Disease clinical trials

Explore recruiting alpha 1 antitrypsin deficiency associated liver disease clinical trials.

Recruiting alpha 1 antitrypsin deficiency associated liver disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alpha 1 Antitrypsin Deficiency Associated Liver Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Austria, Germany, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis

Belgium, Austria, Poland, Ireland, Germany, Italy +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis

Austria, Ireland, Sweden, Spain, Italy, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

Ireland, Sweden, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Alpha 1 Antitrypsin Deficiency Associated Liver Disease trials by city

Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Toronto Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Vancouver Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Montreal Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Calgary Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Edmonton Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Ottawa Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Winnipeg Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Quebec City Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Hamilton Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Kitchener Alpha 1 Antitrypsin Deficiency Associated Liver Disease in London Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Halifax Alpha 1 Antitrypsin Deficiency Associated Liver Disease in New York Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Los Angeles Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Chicago Alpha 1 Antitrypsin Deficiency Associated Liver Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease